KPTI — Karyopharm Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $136.26m
- $248.22m
- $146.03m
- 36
- 43
- 59
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 40.9 | 108 | 210 | 157 | 146 |
Cost of Revenue | |||||
Gross Profit | 38.5 | 105 | 206 | 152 | 141 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 230 | 280 | 308 | 299 | 276 |
Operating Profit | -189 | -172 | -98.3 | -142 | -130 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -200 | -196 | -124 | -165 | -143 |
Provision for Income Taxes | |||||
Net Income After Taxes | -200 | -196 | -124 | -165 | -143 |
Net Income Before Extraordinary Items | |||||
Net Income | -200 | -196 | -124 | -165 | -143 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -200 | -196 | -124 | -165 | -143 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.22 | -2.72 | -1.65 | -2.02 | -1.25 |